Angiotensin-converting enzyme inhibitor use and pneumonia risk in a general population

European Respiratory Journal

Volumn 27, Issue 6, 2006, Pages 1217-1222

  van de Garde, E M W ^a,b   Souverein, P C ^a   van den Bosch, J M M ^b   Deneer, V H M ^b   Leufkens, H G M ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

Angiotensin converting enzyme inhibitor; Angiotensin converting enzyme insertion deletion polymorphism; Pneumonia

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIAC GLYCOSIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; INFLUENZA VACCINE; PROTON PUMP INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST;

ADULT; ARTICLE; ASIAN; CAUCASIAN; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA BASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG USE; FEMALE; HEART FAILURE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RISK ASSESSMENT; RISK REDUCTION; SCORING SYSTEM; AGED; BACTERIAL PNEUMONIA; BRONCHOPNEUMONIA; CASE CONTROL STUDY; COMMUNICABLE DISEASE; COMORBIDITY; CROSS-SECTIONAL STUDY; LOBAR PNEUMONIA; MEDICAL RECORD; MIDDLE AGED; RISK; STATISTICS;

ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BRONCHOPNEUMONIA; CASE-CONTROL STUDIES; COMMUNITY-ACQUIRED INFECTIONS; COMORBIDITY; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INCIDENCE; MALE; MEDICAL RECORD LINKAGE; MIDDLE AGED; ODDS RATIO; PATIENT ADMISSION; PNEUMONIA, BACTERIAL; PNEUMONIA, PNEUMOCOCCAL; RISK ASSESSMENT; STATISTICS;

EID: 33750688180     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.06.00110005     Document Type: Article

References (30)

1. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996; 275: 134-141.
2. Mortensen EM, Coley CM, Singer DE, et al. Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med 2002; 162: 1059-1064.
3. Sekizawa K, Ujiie Y, Itabashi S, Sasaki H, Takishima T. Lack of cough reflex in aspiration pneumonia. Lancet 1990; 335: 1228-1229.
4. Simons RJ, Reynolds HY. Altered immune status in the elderly. Semin Respir Infect 1990; 5: 251-259.
5. Morice AH, Lowry R, Brown MJ, Higenbottam T. Angiotensin-converting enzyme and the cough reflex. Lancet 1987; 2: 1116-1118.
6. Kranzhofer R, Browatzki M, Schmidt J, Kubler W. Angiotensin II activates the proinflammatory transcription factor nuclear factor-kappaB in human monocytes. Biochem Biophys Res Commun 1999; 257: 826-828.
7. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev 2004; 18:2195-2224.
8. Arai T, Sekizawa K, Ohrui T, et al. ACE inhibitors and protection against pneumonia in elderly patients with stroke. Neurology 2005; 64: 573-574.
9. Kaplan RC, Psaty BM. ACE-inhibitor therapy and nosocomial pneumonia. Am J Hypertens 1999; 12: 1161-1162.
10. Ohkubo T, Chapman N, Neal B, Woodward M, Omae T, Chalmers J. Effects of an angiotensin-converting enzyme inhibitor-based regimen on pneumonia risk. Am J Respir Crit Care Med 2004; 169: 1041-1045.
11. Okaishi K, Morimoto S, Fukuo K, et al. Reduction of risk of pneumonia associated with use of angiotensin I converting enzyme inhibitors in elderly inpatients. Am J Hypertens 1999; 12: 778-783.
12. Shibuya S, Murahashi M, Inoue M, Jimi T, Wakayama Y. [ACE inhibitors and its usefulness in the prevention of aspiration pneumonia in chronic cerebrovascular disease patients with asymptomatic swallowing dysfunction]. Rinsho Shinkeigaku 2002; 42: 240-242.
13. Herings RM, Bakker A, Stricker BH, Nap G. Pharmacomorbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts. J Epidemiol Community Health 1992; 46: 136-140.
14. Talbot TR, Hartert TV, Mitchel E, et al. Asthma as a risk factor for invasive pneumococcal disease. N Engl J Med 2005; 352: 2082-2090.
15. Hak E, Bont J, Hoes AW, Verheij TJ. Prognostic factors for serious morbidity and mortality from community-acquired lower respiratory tract infections among the elderly in primary care. Fam Pract 2005; 22: 375-380.
16. Koivula I, Sten M, Makela PH. Risk factors for pneumonia in the elderly. Am J Med 1994; 96: 313-320.
17. Almirall J, Bolibar I, Balanzo X, Gonzalez CA. Risk factors for community-acquired pneumonia in adults: a population-based case-control study. Eur Respir J 1999; 13:349-355.
18. Muller LM, Gorter KJ, Hak E, et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis 2005; 41: 281-288.
19. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989; 11: 954-963.
20. Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004; 292: 1955-1960.
21. Cologne JB, Shibata Y. Optimal case-control matching in practice. Epidemiology 1995; 6: 271-275.
22. D'Agostino R. Tutorial in Biostatistics: propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17: 2265-2281.
23. Kennedy HL. Current utilization trends for beta-blockers in cardiovascular disease. Am J Med 2001; 110: Suppl. 5A, 2S-6S.
24. Sagnella GA, Rothwell MJ, Onipinla. AK, Wicks PD, Cook DG, Cappuccio FP. A population study of ethnic variations in the angiotensin-converting enzyme I/D polymorphism: relationships with gender, hypertension and impaired glucose metabolism. J Hypertens 1999; 17: 657-664.
25. Ye RJ, He QY, Gai J, Shang Y. [A prospective study on the cough mechanism induced by angiotensin-converting enzyme inhibitors in patients with hypertension]. Zhonghua Jie He He Hu Xi Za Zhi 2004; 27: 581-584.
26. Chan WK, Chan TY, Luk WK, Leung VK, Li TH, Critchley JA. A high incidence of cough in Chinese subjects treated with angiotensin converting enzyme inhibitors. Eur J Clin Pharmacol 1993; 44: 299-300.
27. Guevara RE, Butler JC, Marston BJ, Plouffe JF, File TM Jr, Breiman RF. Accuracy of ICD-9-CM codes in detecting community-acquired pneumococcal pneumonia for incidence and vaccine efficacy studies. Am J Epidemiol 1999; 149:282-289.
28. Ruiz M, Ewig S, Marcos MA, et al. Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. Am J Respir Crit Care Med 1999; 160: 397-405.
29. Braun JJ, de Graaff CS, de Goey J, Zwinderman AH, Petit PL. [Community-acquired pneumonia: pathogens and course in patients admitted to a general hospital]. Ned Tijdschr Geneeskd 2004; 148: 836-840.
30. Carroll KC. Laboratory diagnosis of lower respiratory tract infections: controversy and conundrums. J Clin Microbiol 2002; 40: 3115-3120.